ADHD in the Mainstream - Thursday 21st to Saturday 23rd September 2017
The UK Adult ADHD Network (UKAAN) will host its 7th Congress from Thursday 21st to Saturday 23rd September 2017. This 3 day conference will take place at the Mermaid Conference and Events Centre, which will accommodate up to 600 delegates in a Theatre. The venue is situated between the City and the West End, on the North Bank of the Thames, and enjoys spectacular views towards the Tate Modern, Globe Theatre and the Millennium Bridge.
The conference is titled ‘ADHD in the mainstream’ to reflect the rapid increase in recognition and treatment of ADHD by adult mental health services. ADHD is a common disorder affecting around 5% of children and 3% of adults, with symptoms and impairments that overlap with other common mental health disorders. The role that ADHD plays in the health of many adults presenting with mental health problems is now much more widely recognised, yet recent evidence suggests that in many cases the disorder still goes unrecognised or treated. Our vision is to bring ADHD into the mainstream, so that all mental health professionals have the knowledge and understanding to diagnose and treat ADHD, in the same way as other common mental health disorders.
Common symptoms of ADHD include severe levels of inattention, distractibility, disorganisation, over activity, restlessness, impulsiveness and mood lability that lead to clinical and psychosocial impairments. Some people manage ADHD symptoms well in their daily lives, yet may still suffer from educational and occupational problems due to inattention and disorganisation, and report difficulties with sleep problems, emotional lability and restlessness. ADHD is often associated with specific learning difficulties and is a common problem in higher education. ADHD is also seen in high rates in people with other significant mental health problems including substance abuse, unstable mood states, anxiety, depression, aggression, criminal behaviour and emerging or developed personality disorder.
Despite the considerable psychiatric morbidity associated with ADHD and the availability of effective pharmacological and non-pharmacological treatments, the disorder often goes unrecognised and untreated in people as they grow older. This leads to unnecessary distress to individuals, ineffective targeting of treatments, poor control over chronic mental health problems and the development of adult onset disorders later in life. Nevertheless, in many regions of the UK and across the world there has been a stepped increase in the recognition of ADHD by adult mental health services reflected in a rapid rise in the availability of clinical services. Licensed drug treatments for adult ADHD are now available for the first time, including both stimulant and non-stimulant mediation and recommendations from guideline groups such as the National Institute of Health and Clinical Excellence (NICE). The importance of concurrent psychological treatments is also recognised, and mainstream psychological treatment services need to develop the understanding and skills required to manage mental health problems related to ADHD. This meeting therefore aims to raise the level of awareness, knowledge and expertise among health care professionals about people with ADHD and provide a better understanding of the persistence of the disorder, the development of comorbid mental health problems and the delivery of effective treatments.
The program will be delivered by prominent opinion leaders, clinical experts and internationally recognised investigators and is designed to cover key topics relevant to the diagnosis and treatment of ADHD from adolescence to early and late adulthood. The selection of speakers is particular important so that the audience can hear directly from the most experienced professionals working in this rapidly developing area of clinical psychiatry.
Professor Philip Asherson